Clinical impact of hepatitis B and C virus envelope glycoproteins

World Journal of Gastroenterology

Volumn 19, Issue 5, 2013, Pages 654-664

  Jeulin, Hélène ^a,b   Velay, Aurélie ^a   Murray, John ^c,d   Schvoerer, Evelyne ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Clinical outcome; Hepatitis B; Hepatitis C; Viral envelope glycoproteins

Indexed keywords

ADEFOVIR; ALPHA2B INTERFERON PLUS RIBAVIRIN; ASIALOGLYCOPROTEIN RECEPTOR; CD45 ANTIGEN; CD81 ANTIGEN; CLAUDIN; ENTECAVIR; GLYCOPROTEIN; GLYCOPROTEIN E2; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; RECOMBINANT VACCINE; TENOFOVIR;

APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE COURSE; GENE EXPRESSION; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; NONHUMAN; REVIEW; VACCINATION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS REPLICATION;

EID: 84873659510     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i5.654     Document Type: Review

References (68)

1. Lavanchy D. Evolving epidemiology of hepatitisC virus. Clin Microbiol Infect 2011; 17: 107-115. [PMID: 21091831 DOI: 10.1111/j.1469-0691.2010.03432.x]
2. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, Govindarajan S, Purcell RH, Chisari FV. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002; 99: 15661-15668. [PMID: 12441397 DOI: 10.1073/pnas.202608]
3. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, McKeating JA. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007; 132: 667-678. [PMID: 17258731 DOI: 10.1053/j.gastro.2006.12.008]
4. Chen Y, Qian F, Yuan Q, Li X, Wu W, Guo X, Li L. Mutations in hepatitis B virus DNA from patients with coexisting HBsAg and anti-HBs. J Clin Virol 2011; 52: 198-203. [PMID: 21840251 DOI: 10.1016/j.jcv.2011.07.011]
5. Baumert TF, Thimme R, von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007; 13: 82-90. [PMID: 17206757]
6. Murray JM, Purcell RH, Wieland SF. The half-life of hepatitis B virions. Hepatology 2006; 44: 1117-1121. [PMID: 17058221 DOI: 10.1002/hep.21364]
7. Dandri M, Murray JM, Lutgehetmann M, Volz T, Lohse AW, Petersen J. Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia. Hepatology 2008; 48: 1079-1086. [PMID: 18697217 DOI: 10.1002/hep.22469]
8. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, Layden TJ. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35. [PMID: 10882578 DOI: 10.1086/315661]
9. Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, Litwin S, Furman PA, Jilbert AR, Mason WS. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001; 75: 311-322. [PMID: 11119601 DOI: 10.1128/JVI.75.1.311-322.2001]
10. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48: 88-98. [PMID: 18537180 DOI: 10.1002/ hep.22295]
11. Glebe D, Urban S. Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol 2007; 13: 22-38. [PMID: 17206752]
12. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 2002; 99: 15655-15660. [PMID: 12432097 DOI: 10.1073/pnas.232137699]
13. Zoulim F, Berthillon P, Guerhier FL, Seigneres B, Germon S, Pichoud C, Cheng YC, Trepo C. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies. J Gastroenterol Hepatol 2002; 17 Suppl: S460-S463. [PMID: 12534778 DOI: 10.1046/j.1440-1746.17.s4.10.x]
14. De Meyer S, Gong ZJ, Suwandhi W, van Pelt J, Soumillion A, Yap SH. Organ and species specificity of hepatitis B virus (HBV) infection: a review of literature with a special reference to preferential attachment of HBV to human hepatocytes. J Viral Hepat 1997; 4: 145-153. [PMID: 9181523 DOI: 10.1046/ j.1365-2893.1997.00126.x]
15. Lütgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, Pollok JM, Lohse AW, Petersen J, Urban S, Dandri M. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 2012; 55: 685-694. [PMID: 22031488 DOI: 10.1002/hep.24758]
16. Bruss V, Gerhardt E, Vieluf K, Wunderlich G. Functions of the large hepatitis B virus surface protein in viral particle morphogenesis. Intervirology 1996; 39: 23-31. [PMID: 8957666 DOI: 10.1159/000150471]
17. Salisse J, Sureau C. A function essential to viral entry underlies the hepatitis B virus "a" determinant. J Virol 2009; 83: 9321-9328. [PMID: 19570861 DOI: 10.1128/JVI.00678-09]
18. Bauer T, Weinberger K, Jilg W. Variants of two major T cell epitopes within the hepatitis B surface antigen are not recognized by specific T helper cells of vaccinated individuals. Hepatology 2002; 35: 455-465. [PMID: 11826423 DOI: 10.1053/ jhep.2002.30903]
19. Glebe D. Attachment sites and neutralising epitopes of hepatitis B virus. Minerva Gastroenterol Dietol 2006; 52: 3-21. [PMID: 16554703]
20. Dash S, Rao KV, Panda SK. Receptor for pre-S1(21-47) component of hepatitis B virus on the liver cell: role in virus cell interaction. J Med Virol 1992; 37: 116-121. [PMID: 1629710 DOI: 10.1002/jmv.1890370208]
21. Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev 1995; 75: 591-609. [PMID: 7624395]
22. Hertogs K, Leenders WP, Depla E, De Bruin WC, Meheus L, Raymackers J, Moshage H, Yap SH. Endonexin II, present on human liver plasma membranes, is a specific binding protein of small hepatitis B virus (HBV) envelope protein. Virology 1993; 197: 549-557. [PMID: 8249278 DOI: 10.1006/ viro.1993.1628]
23. de Bruin WC, Leenders WP, Moshage H, van Haelst UJ. Species specificity for HBsAg binding protein endonexin II. J Hepatol 1996; 24: 265-270. [PMID: 8778191 DOI: 10.1016/ S0168-8278(96)80003-1]
24. De Meyer S, Gong ZJ, Hertogs K, Depla E, van Pelt JF, Ros kams T, Maertens G, Yap SH. Influence of the administration of human annexin V on in vitro binding of small hepatitis B surface antigen to human and to rat hepatocytes and on in vitro hepatitis B virus infection. J Viral Hepat 2000; 7: 104-114. [PMID: 10760040 DOI: 10.1046/j.1365-2893.1999.00167.x]
25. Yamada M, Oeda A, Jung J, Iijima M, Yoshimoto N, Niimi T, Jeong SY, Choi EK, Tanizawa K, Kuroda S. Hepatitis B virus envelope L protein-derived bio-nanocapsules: mechanisms of cellular attachment and entry into human hepatic cells. J Control Release 2012; 160: 322-329. [PMID: 22100387 DOI: 10.1016/ j.1conrel.2011.11.004]
26. Leistner CM, Gruen-Bernhard S, Glebe D. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol 2008; 10: 122-133. [PMID: 18086046 DOI: 10.1111/ j.1462-5822.2007.01023.x]
27. Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 2007; 46: 1759-1768. [PMID: 18046710 DOI: 10.1002/hep.21896]
28. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010; 58: 258-266. [PMID: 20116937 DOI: 10.1016/j.patbio.2009.11.001]
29. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012; 122: 529-537. [PMID: 22251702 DOI: 10.1172/JCI58847]
30. Maini MK, Bertoletti A. How can the cellular immune response control hepatitis B virus replication? J Viral Hepat 2000; 7: 321-326. [PMID: 10971819 DOI: 10.1046/j.1365-2893.2000.00234. x]
31. Desmond CP, Bartholomeusz A, Gaudieri S, Revill PA, Lewin SR. A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir Ther 2008; 13: 161-175. [PMID: 18505168]
32. Pajot A, Michel ML, Mancini-Bourgine M, Ungeheuer MN, Ojcius DM, Deng Q, Lemonnier FA, Lone YC. Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects. Microbes Infect 2006; 8: 2783-2790. [PMID: 17045504 DOI: 10.1016/j.micinf.2006.08.009]
33. Manigold T, Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect Dis 2007; 7: 804-813. [PMID: 18045563 DOI: 10.1016/S1473-3099(07)70289-X]
34. van den Berg R, van Hoogstraten I, van Agtmael M. Nonresponsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev 2009; 11: 157-164. [PMID: 19654857]
35. Sjogren MH. Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination. Am J Med 2005; 118 Suppl 10A: 34S-39S. [PMID: 16271539 DOI: 10.1016/ j.amjmed.2005.07.012]
36. Glaser R, Kiecolt-Glaser JK, Bonneau RH, Malarkey W, Kennedy S, Hughes J. Stress-induced modulation of the immune response to recombinant hepatitis B vaccine. Psychosom Med 1992; 54: 22-29. [PMID: 1553399]
37. Krey T, d'Alayer J, Kikuti CM, Saulnier A, Damier-Piolle L, Petitpas I, Johansson DX, Tawar RG, Baron B, Robert B, England P, Persson MA, Martin A, Rey FA. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog 2010; 6: e1000762. [PMID: 20174556 DOI: 10.1371/journal.ppat.1000762]
38. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17: 589-595. [PMID: 21516087 DOI: 10.1038/nm.2341]
39. Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007; 104: 6025-6030. [PMID: 17392433 DOI: 10.1073/ pnas.0607026104]
40. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005; 79: 8217-8229. [PMID: 15956567 DOI: 10.1128/JVI.79.13.8217-8229.2005]
41. Panjaworayan N, Brown CM. Effects of HBV Genetic Variability on RNAi Strategies. Hepat Res Treat 2011; 2011: 367908. [PMID: 21760994 DOI: 10.1155/2011/367908]
42. Simmonds P. Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol 2004; 85: 3173-3188. [PMID: 15483230 DOI: 10.1099/vir.0.80401-0]
43. Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res 2007; 127: 164-176. [PMID: 17383765 DOI: 10.1016/j.viruses.2007.02.021]
44. Bowyer SM, Sim JG. Relationships within and between genotypes of hepatitis B virus at points across the genome: footprints of recombination in certain isolates. J Gen Virol 2000; 81: 379-392. [PMID: 10644836]
45. Pollicino T, Amaddeo G, Restuccia A, Raffa G, Alibrandi A, Cutroneo G, Favaloro A, Maimone S, Squadrito G, Raimondo G. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology 2012; 56: 434-443. [PMID: 22271491 DOI: 10.1002/ hep.25592]
46. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007; 20: 23-38. [PMID: 17223621 DOI: 10.1128/ CMR.00010-06]
47. Chayama K, Hayes CN. Hepatitis C virus: How genetic variability affects pathobiology of disease. J Gastroenterol Hepatol 2011; 26 Suppl 1: 83-95. [PMID: 21199518 DOI: 10.1111/ j.1440-1746.2010.06550.x]
48. Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, McKeating JA. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 2008; 82: 12020-12029. [PMID: 18829747 DOI: 10.1128/JVI.01569-08]
49. Zhong J, Gastaminza P, Chung J, Stamataki Z, Isogawa M, Cheng G, McKeating JA, Chisari FV. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol 2006; 80: 11082-11093. [PMID: 16956932 DOI: 10.1128/ JVI.01307-06]
50. Keck ZY, Xia J, Wang Y, Wang W, Krey T, Prentoe J, Carlsen T, Li AY, Patel AH, Lemon SM, Bukh J, Rey FA, Foung SK. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog 2012; 8: e1002653. [PMID: 22511875]
51. Gal-Tanamy M, Keck ZY, Yi M, McKeating JA, Patel AH, Foung SK, Lemon SM. In vitro selection of a neutralizationresistant hepatitis C virus escape mutant. Proc Natl Acad Sci USA 2008; 105: 19450-19455. [PMID: 19052239 DOI: 10.1073/pnas.0809879105]
52. Chang MH. Hepatitis B virus mutation in children. Indian J Pediatr 2006; 73: 803-807. [PMID: 17006039 DOI: 10.1007/ BF02790390]
53. Hsu HY, Chang MH, Ni YH, Chiang CL, Chen HL, Wu JF, Chen PJ. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. J Infect Dis 2010; 201: 1192-1200. [PMID: 20210630 DOI: 10.1086/651378]
54. Tabor E. Infections by hepatitis B surface antigen gene mutants in Europe and North America. J Med Virol 2006; 78 Suppl 1: S43-S47. [PMID: 16622882 DOI: 10.1002/jmv.20606]
55. Kamili S, Sozzi V, Thompson G, Campbell K, Walker CM, Locarnini S, Krawczynski K. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 2009; 49: 1483-1491. [PMID: 19274751 DOI: 10.1002/hep.22796]
56. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011; 54: 1273-1285. [PMID: 21236312 DOI: 10.1016/j.hep.2010.09.040]
57. Di Lorenzo C, Angus AG, Patel AH. Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses 2011; 3: 2280-2300. [PMID: 22163345 DOI: 10.3390/v3112280]
58. Takkenberg RB, Weegink CJ, Zaaijer HL, Reesink HW. New developments in antiviral therapy for chronic hepatitis B. Vox Sang 2010; 98: 481-494. [PMID: 19951307 DOI: 10.1111/ j.1423-0410.2009.01282.x]
59. Bhattacharya D, Thio CL. Review of hepatitis B therapeutics. Clin Infect Dis 2010; 51: 1201-1208. [PMID: 20954965 DOI: 10.1086/656624]
60. Tang YZ, Liu L, Pan MM, Wang YM, Deng GH. Evolutionary pattern of full hepatitis B virus genome during sequential nucleos(t)ide analog therapy. Antiviral Res 2011; 90: 116-125. [PMID: 21440005 DOI: 10.1016/j.antiviral.2011.03.183]
61. Maekawa S, Enomoto N. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol 2009; 44: 1009-1015. [PMID: 19756352 DOI: 10.1007/s00535-009-0126-7]
62. Kurbanov F, Tanaka Y, Matsuura K, Sugauchi F, Elkady A, Khan A, Hasegawa I, Ohno T, Tokuda H, Mizokami M. Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin. J Infect Dis 2010; 201: 1663-1671. [PMID: 20420509 DOI: 10.1086/652500]
63. Hofmann WP, Sarrazin C, Kronenberger B, Schönberger B, Bruch K, Zeuzem S. Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients. J Infect Dis 2003; 187: 982-987. [PMID: 12660945 DOI: 10.1086/368221]
64. Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, Dustin LB, Dibisceglie AM. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 2005; 79: 3071-3083. [PMID: 15709027 DOI: 10.1128/JVI.79.5.3071-3083.2005]
65. Gaudy C, Moreau A, Veillon P, Temoin S, Lunel F, Goudeau A. Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome. J Clin Microbiol 2003; 41: 3615-3622. [PMID: 12904364 DOI: 10.1128/JCM.41.8.3615-3622.2003]
66. Aurora R, Donlin MJ, Cannon NA, Tavis JE. Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest 2009; 119: 225-236. [PMID: 19104147 DOI: 10.1172/JCI37085]
67. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol 2011; 54: 566-576. [PMID: 21146244 DOI: 10.1016/j.hep.2010.10.014]
68. Ploss A, Dubuisson J. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut 2012; 61 Suppl 1: i25-i35. [PMID: 22504917 DOI: 10.1136/gutjnl-2012-302048]